Clinical CDMO Neobiosis operates as a clinical stage CDMO with capabilities in isolation of tissues, cells and extracellular vesicles from perinatal donors and supports FDA-approved clinical trial pathways, presenting a route for CRO/CDMO collaborations and in-licensing opportunities for partners seeking translational manufacturing and early-stage clinical support.

Regenerative Focus The company’s emphasis on anti-aging and regenerative medicine using perinatal tissues and EVs positions it to engage with biotech firms pursuing regenerative therapies, with potential for co-development, IP licensing, or contract manufacturing of novel biologics and cellular products.

Strategic Footprint Two production facilities plus an R&D lab within a university-affiliated biotech institute suggest strong collaboration channels, access to academic partnerships, and proximity to clinical research networks that can be leveraged for joint development programs and sponsored research agreements.

Mid-market Revenue With annual revenue in the 25 to 50 million range and a compact employee base, Neobiosis may be an attractive partner for focused, high-value projects where agility and specialized capabilities deliver faster time-to-clinic manufacturing and scalable tech transfer for mid-market biotech clients.

Donor Tissue Expertise Specialization in healthy full-term birth tissues, including umbilical cord and amniotic fluid, creates a differentiated positioning for partners seeking validated perinatal sources, potential for strategic sourcing agreements, and exclusive or preferred-provider arrangements for clinical trial materials.